eli lilly glp 1 program is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating The Bioinformatics Behind Eli Lilly's

The best evidence available is that BPC-157 results in improved outcomes in muscle, tendon, ligament, and bone injury models in animals. There are probably trials ongoing, but if we are being honest about the totality of evidence available to us right now , it is irresponsible to claim either way that BPC-157 does or does not increase performance

Before starting semaglutide or tirzepatide after bariatric surgery, your medical team must confirm your nutrient levels are adequate and establish a supplementation plan that accounts for both surgery and medication effects

March 21, 2024: Anticipating a Surge of Ozempic Lawsuits in New Jersey Courts The Ozempic lawsuit will soon become the Ozempic lawsuits

Sergey Terushkin, MD, FACS Compassionate, affordable care for lasting weight loss